Barclays PLC Reports New 5.65% Stake in Amicus Therapeutics Inc (FOLD)

On May 14, 2026, Barclays PLC filed a Schedule 13G with the SEC, reporting a significant new ownership position in Amicus Therapeutics Inc (FOLD). As of the event date on March 31, 2026, Barclays PLC beneficially owns 17,755,672 shares of common stock, representing a 5.65% stake in the company. This filing marks an increase from a previously reported 0% position, crossing the 5% regulatory threshold. The reported shares include 17,747,658 shares over which Barclays PLC holds sole voting and dispositive power, and 8,014 shares with shared voting and dispositive power. The securities are held by several subsidiaries, including Barclays Bank PLC, Barclays Capital Inc., and Barclays Capital Securities Ltd. In accordance with Rule 13d-1(b), Barclays PLC certified that these shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The total value of the holding is estimated at approximately $257.28 million based on the filing details.